Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-28T00:33:32.291Z Has data issue: false hasContentIssue false
  • English
  • Français

Perfusion SPECT and FDG-PET

Published online by Cambridge University Press:  10 June 2011

Karl Herholz
Karl Herholz*
Affiliation:
Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
*
Correspondence should be addressed to: Karl Herholz, MD, FRCP, Professor in Clinical Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, 27 Palatine Road, Manchester M20 3LJ, UK. Phone: +44 161-275-0014; Fax: +44 161-275-0003. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Both perfusion SPECT and FDG-PET provide images that closely reflect neuronal activity. There is a characteristic regional impairment in Alzheimer's disease (AD) that involves mainly the temporo-parietal association cortices, mesial temporal structures and to a more variable degree also the frontal association cortex. This pattern of functional impairment can provide a biomarker for diagnosis of AD and other neurodegenerative dementias at the clinical stage of mild cognitive impairment, and for monitoring of progression. FDG-PET is quantitatively more accurate and thus better suited to multicenter studies than perfusion SPECT. Regional metabolic and blood flow changes are closely related to clinical symptoms, and most areas involved in these changes will also develop significant cortical atrophy. FDG-PET is complementary to amyloid PET, which targets a molecular marker that does not have a close relation to current symptoms. Current restrictions in the availability and cost of FDG-PET are being reduced, as oncological FDG-PET is being adopted as a standard clinical service in most countries. Limitations in the availability of trained staff should be overcome by training programs set up by professional organizations. Against the background of the development of new criteria for diagnosing AD before the onset of dementia, FDG-PET is expected to play an increasing role in diagnosing patients at an early stage of AD and in clinical trials of drugs aimed at preventing or delaying the onset of dementia.

Keywords

PETSPECTperfusionglucose metabolismdementiaAlzheimer's diseaseclinical trials
Type
Review Article
Information
International Psychogeriatrics , Volume 23 , Supplement S2: Clinical use of neuroimaging in dementia: an international perspective , September 2011 , pp. S25 - S31
Copyright
Copyright © International Psychogeriatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aisen, P. S. et al. (2011). Report of the task force on designing clinical trials in early (predementia) AD. Neurology, 76, 280–286.CrossRefGoogle ScholarPubMed
Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I. and Reiman, E. M. (2002). Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. American Journal of Psychiatry, 159, 738–745.CrossRefGoogle ScholarPubMed
DevousM. D., Sr M. D., Sr. (2002). Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. European Journal of Nuclear Medicine and Molecular Imaging, 29, 1685–1696.CrossRefGoogle ScholarPubMed
Dougall, N., Nobili, F. and Ebmeier, K. P. (2004). Predicting the accuracy of a diagnosis of Alzheimer's disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Research: Neuroimaging, 131, 157–168.CrossRefGoogle ScholarPubMed
Dubois, B. et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734–746.CrossRefGoogle ScholarPubMed
Foster, N. L. et al. (2007). FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 130, 2616–2635.CrossRefGoogle ScholarPubMed
Frisoni, G. B. et al. (2007). The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain, 130, 720–730.CrossRefGoogle ScholarPubMed
Grady, C. L., Haxby, J. V., Schlageter, N. L., Berg, G. and Rapoport, S. I. (1986). Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology, 36, 1390–1392.CrossRefGoogle ScholarPubMed
Habeck, C. et al. (2008). Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. NeuroImage, 40, 1503–1515.CrossRefGoogle ScholarPubMed
Haense, C., Herholz, K., Jagust, W. J. and Heiss, W. D. (2009). Performance of FDG PET for detection of Alzheimer's disease in two independent multicenter samples (NEST-DD and ADNI). Dementia and Geriatric Cognitive Disorders, 28, 259–266.CrossRefGoogle ScholarPubMed
Haxby, J. V. et al. (1990). Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Archives of Neurology, 47, 753–760.CrossRefGoogle ScholarPubMed
Heiss, W. D., Kessler, J., Mielke, R., Szelies, B. and Herholz, K. (1994). Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease: a neuropsychological, EEG, and PET investigation. Dementia, 5, 88–98.Google ScholarPubMed
Herholz, K. (2003). PET studies in dementia. Annals of Nuclear Medicine, 17, 79–89.CrossRefGoogle ScholarPubMed
Herholz, K. (2010). Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Reviews in Neurotherapy, 10, 1667–1673.CrossRefGoogle ScholarPubMed
Herholz, K. and Heiss, W. D. (2004). PET in clinical neurology. Molecular Imaging and Biology, 6, 239–269.CrossRefGoogle ScholarPubMed
Herholz, K. et al. (2002a). Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage, 17, 302–316.CrossRefGoogle ScholarPubMed
Herholz, K. et al. (2002b). Direct comparison of spatially normalized PET and SPECT scans in Alzheimer disease. Journal of Nuclear Medicine, 43, 21–26.Google Scholar
Hirono, N., Hashimoto, M., Ishii, K., Kazui, H. and Mori, E. (2004). One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neuroscience, 16, 488–492.CrossRefGoogle ScholarPubMed
Holthoff, V. A. et al. (2005). Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biological Psychiatry, 57, 412–421.CrossRefGoogle ScholarPubMed
Hort, J. et al. (2010). EFNS guidelines for the diagnosis and management of Alzheimer's disease. European Journal of Neurology, 17, 1236–1248.CrossRefGoogle ScholarPubMed
Hossmann, K. A., Hossmann, V. and Takagi, S. (1978). Microsphere analysis of local cerebral and extracerebral blood flow after complete ischemia of the cat brain for one hour. Journal of Neurology, 218, 275–285.CrossRefGoogle ScholarPubMed
Ishii, K. et al. (2006). Fully automatic diagnostic system for early- and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP. European Journal of Nuclear Medicine and Molecular Imaging, 33, 575–583.CrossRefGoogle ScholarPubMed
Jagust, W. J., Friedland, R. P., Budinger, T. F., Koss, E. and Ober, B. (1988). Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology, 38, 909–912.CrossRefGoogle ScholarPubMed
Jagust, W. et al. (2001). SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology, 56, 950–956.CrossRefGoogle ScholarPubMed
Johnson, K. A. et al. (1998). Preclinical prediction of Alzheimer's disease using SPECT. Neurology, 50, 1563–1571.CrossRefGoogle ScholarPubMed
Juni, J. E. et al. (1998). Procedure guideline for brain perfusion SPECT using technetium-99m radiopharmaceuticals. Journal of Nuclear Medicine, 39, 923–926.Google ScholarPubMed
Kadir, A. et al. (2008). Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Annals of Neurology, 63, 621–631.CrossRefGoogle ScholarPubMed
Kasischke, K. A., Vishwasrao, H. D., Fisher, P. J., Zipfel, W. R. and Webb, W. W. (2004). Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science, 305, 99–103.CrossRefGoogle ScholarPubMed
Landau, S. M. et al. (2009). Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging. Epublished ahead of print, doi:10.1016/j.neurobiolaging.2009.07.002.Google ScholarPubMed
Lassen, N. A. and Ingvar, D. H. (1963). Regional cerebral blood flow measurement in man. Archives of Neurology, 9, 615–622.CrossRefGoogle Scholar
Lobotesis, K. et al. (2001). Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology, 56, 643–649.CrossRefGoogle Scholar
McNeill, R. et al. (2007). Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 78, 350–355.CrossRefGoogle ScholarPubMed
Mega, M. S. et al. (2005). Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomographic study. Archives of Neurology, 62, 721–728.CrossRefGoogle ScholarPubMed
Merhof, D. et al. (2011). Optimized data preprocessing for multivariate analysis applied to (99m)Tc-ECD SPECT data sets of Alzheimer's patients and asymptomatic controls. Journal of Cerebral Blood Flow and Metabolism, 31, 371–383.CrossRefGoogle ScholarPubMed
Mielke, R., Herholz, K., Grond, M., Kessler, J. and Heiss, W. D. (1994). Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia, 5, 36–41.Google ScholarPubMed
Minoshima, S., Frey, K. A., Koeppe, R. A., Foster, N. L. and Kuhl, D. E. (1995). A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine, 36, 1238–1248.Google ScholarPubMed
Minoshima, S., Foster, N. L., Sima, A. A., Frey, K. A., Albin, R. L. and Kuhl, D. E. (2001). Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Annals of Neurology, 50, 358–365.CrossRefGoogle ScholarPubMed
Mosconi, L. et al. (2005). Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology, 64, 1860–1867.CrossRefGoogle Scholar
Mosconi, L. et al. (2008). Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. Journal of Nuclear Medicine, 49, 390–398.CrossRefGoogle ScholarPubMed
Neirinckx, R. D., Burke, J. F., Harrison, R. C., Forster, A. M., Andersen, A. R. and Lassen, N. A. (1988). The retention mechanism of technetium-99m-HM-PAO: intracellular reaction with glutathione. Journal of Cerebral Blood Flow and Metabolism, 8, S4–12.CrossRefGoogle ScholarPubMed
O'Brien, J. T., Eagger, S., Syed, G. M., Sahakian, B. J. and Levy, R. (1992). A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 55, 1182–1187.CrossRefGoogle ScholarPubMed
Pellerin, L. and Magistretti, P. J. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proceedings of the National Academy of Sciences of the United States of America, 91, 10625–10629.CrossRefGoogle ScholarPubMed
Rowe, C. C. et al. (2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31, 1275–1283.CrossRefGoogle ScholarPubMed
Salas-Gonzalez, D. et al. (2009). Analysis of SPECT brain images for the diagnosis of Alzheimer's disease using moments and support vector machines. Neuroscience Letters, 461, 60–64.CrossRefGoogle ScholarPubMed
Smith, G. S. et al. (1992). Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications. Archives of Neurology, 49, 1142–1150.CrossRefGoogle ScholarPubMed
Sokoloff, L. (1977). Relation between physiological function and energy metabolism in the central nervous system. Journal of Neurochemistry, 29, 13–26.CrossRefGoogle ScholarPubMed
Staffen, W. et al. (2006). Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation. Journal of Neural Transmission, 113, 195–203.CrossRefGoogle Scholar
Talbot, P. R., Lloyd, J. J., Snowden, J. S., Neary, D. and Testa, H. J. (1998). A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? Journal of Neurology, Neurosurgery and Psychiatry, 64, 306–313.CrossRefGoogle ScholarPubMed
Trojanowski, J. Q. et al. (2010). Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dementia, 6, 230–238.CrossRefGoogle ScholarPubMed
Tzimopoulou, S. T. E. et al. (2010). A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. Journal of Alzheimer's Disease, 22, 1241–1256.CrossRefGoogle ScholarPubMed
Varrone, A. et al. (2009a) EANM procedure guidelines for PET brain imaging using [(18)F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 36, 2103–2110.CrossRefGoogle ScholarPubMed
Varrone, A., Sjoholm, N., Eriksson, L., Gulyas, B., Halldin, C. and Farde, L. (2009b). Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. European Journal of Nuclear Medicine and Molecular Imaging, 36, 1639–1650.CrossRefGoogle ScholarPubMed
Villain, N. et al. (2008). Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. Journal of Neuroscience, 28, 6174–6181.CrossRefGoogle ScholarPubMed
Villain, N. et al. (2010) Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain, 133, 3301–3314.CrossRefGoogle ScholarPubMed